vinorelbine (navelbine) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Vinorelbine (trade name Navelbine) is a semi-synthetic vinca-alkaloid with a broad spectrum of anti-tumour activity. Vinorelbine is a mitotic spindle poison that impairs chromosomal segregation during mitosis. It blocks cells at G2/M. Microtubules (derived from polymers of tubulin) are the principal target of vinorelbine. Vinorelbine was developed by Pierre Fabre under licence from the CNRS in France. NAVELBINE (vinorelbine tartrate) as a single agent or in combination is indicated for the first line treatment of non small cell lung cancer and advanced breast cancer.   NCATS

Chemistry

  • SMILES: CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
  • InChIKey: GBABOYUKABKIAF-IELIFDKJSA-N
  • Mol. Mass: 778.95
  • ALogP: 4.75
  • ChEMBL Molecules:
    vinorelbine  
    vinorelbine tartrate  
    vinorelbine tartrate  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$7.8538 - $86.9732
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

5'-anhydrovinblastine | 5'-noranhydrovinblastine | 5'-nor-anhydrovinblastine | c'-norvincaleukoblastine, 3',4'-didehydro-4'-deoxy- | kw 2307 | kw-2307 | liposomal vinorelbine | navelbin | navelbine | navelbine base | nor-5'-anhydrovinblastine | noranhydrovinblastine tartrate | vinorelbin | vinorelbina | vinorelbin ditartrate | vinorelbine | vinorelbine base | vinorelbine ditartarate | vinorelbine ditartrate | vinorelbine (ditartrate) | vinorelbine ditartrate salt hydrate | vinorelbine tartrate | vinorelbinum

Organizations (459)

Research & Development (448)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (98)

Approved Indications (2)


 

Breast Neoplasms (approved 1994)

Carcinoma, Non-Small-Cell Lung (approved 1994)

Experimental Indications - Clinical Trial Phases 1-4 (98)


 

Adenocarcinoma (Phase 2)

Adenocarcinoma of Lung (Phase 3)

Adolescent (Phase 2)

Amyloidosis (Phase 2)

Brain Neoplasms (Phase 2)

Breast (Phase 1/Phase 2)

Breast Carcinoma In Situ (Phase 2)

Breast Diseases (Phase 2)

Breast Neoplasms (Phase 4)

Breast Neoplasms, Male (Phase 2)

Bronchial Neoplasms (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Bronchogenic (Phase 3)

Carcinoma, Ductal, Breast (Phase 3)

Carcinoma, Islet Cell (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 4)

Carcinoma, Renal Cell (Phase 1)

Carcinoma, Squamous Cell (Phase 3)

Chemoradiotherapy (Phase 2)

Child (Phase 2)

Choroidal Neovascularization (Phase 1)

Circulating Tumor DNA (Phase 2)

Cisplatin (Phase 2)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Cytoreduction Surgical Procedures (Phase 2)

Desmoplastic Small Round Cell Tumor (Phase 1/Phase 2)

Diffuse Intrinsic Pontine Glioma (Phase 2)

Disease-Free Survival (Phase 2/Phase 3)

Disease Progression (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Drugs, Investigational (Phase 2)

Endometrial Neoplasms (Phase 1)

Epidermal Growth Factor (Phase 3)

Esophageal Neoplasms (Phase 3)

Esophageal Squamous Cell Carcinoma (Phase 3)

Fallopian Tube Neoplasms (Phase 2)

Fatigue (Phase 2)

Genetic Predisposition to Disease (Phase 3)

Glioma (Phase 2)

Granulocyte-Macrophage Colony-Stimulating Factor (Phase 2)

Hamartoma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Hodgkin Disease (Phase 3)

Immunotherapy (Phase 2)

Inflammatory Breast Neoplasms (Phase 2)

Intestinal Neoplasms (Phase 1)

Kidney Neoplasms (Phase 2)

Leiomyosarcoma (Phase 1)

Leukemia (Phase 1/Phase 2)

Lung Diseases (Phase 3)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Large-Cell, Anaplastic (Phase 3)

Lymphoma, Large-Cell, Immunoblastic (Phase 1/Phase 2)

Lymphoma, Non-Hodgkin (Phase 3)

Lymphoma, T-Cell, Peripheral (Phase 2)

Medulloblastoma (Phase 2)

Melanoma (Phase 2)

Mesothelioma (Phase 3)

Mesothelioma, Malignant (Phase 3)

Multiple Myeloma (Phase 2)

Musculoskeletal Diseases (Phase 2)

Mutation (Phase 3)

Neoadjuvant Therapy (Phase 2)

Neoplasm Metastasis (Phase 3)

Neoplasms ()

Neoplasms, Connective and Soft Tissue (Phase 2)

Neuroblastoma (Phase 2)

Neuroendocrine Tumors (Phase 2)

Oncogene Proteins (Phase 2)

Osteosarcoma (Phase 2)

Ovarian Diseases (Phase 1/Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Pathology (Phase 2)

Pheochromocytoma (Phase 1)

Prostatic Neoplasms (Phase 2)

Radiation Oncology (Phase 2)

Radiotherapy (Phase 3)

Respiratory Tract Diseases (Phase 3)

Respiratory Tract Neoplasms (Phase 3)

Rhabdomyosarcoma (Phase 3)

Rhabdomyosarcoma, Alveolar (Phase 3)

Rhabdomyosarcoma, Embryonal (Phase 3)

Sarcoma (Phase 3)

Sarcoma, Ewing (Phase 2)

Small Cell Lung Carcinoma (Phase 1/Phase 2)

Stomach Neoplasms (Phase 2)

Thoracic Neoplasms (Phase 3)

Thymidylate Synthase (Phase 2)

Thyroid Neoplasms (Phase 1)

Triple Negative Breast Neoplasms (Phase 3)

Urinary Bladder Neoplasms (Phase 1)

Uterine Cervical Neoplasms (Phase 3)

Vaginal Neoplasms (Phase 1)

Vinorelbine (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 438
  • # of Trial Organizations: 448

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue